Acadia Pharmaceuticals Inc. (ACAD) stock slips, “Neutral” rating reiterated by Roth Capital Analysts

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares fell on in early trade Wednesday with lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Roth Capital analysts reiterated its Neutral rating on Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) in a note to investors, making it one of the more closely watched stocks on Wall Street. With a rating of Neutral on the shares, the company has a 52-week high of $43.30. The one-year price target of $44.78 is higher than the opening price of $24.18, that has caused a fair amount of other analysts to issue statements on the company recently. Usually, after analysts issue a “reiterated rating” report on a stock, they will subsequently issue recurring revisions, such as a price target change.

U.S. stocks mostly climbed on Wednesday as crude-oil prices traded above $51 a barrel.

The Dow Jones Industrial Average DJIA, +0.18% gained 33 points, or 0.2% at 18,195, the S&P 500 index SPX, +0.07% advanced 2 points, or less than 0.1%, at 2,141, while the Nasdaq Composite Index COMP, -0.08% traded little-changed at 5,240.

U.S. stocks closed higher Tuesday as investors welcomed stronger-than-expected quarterly results from a host of companies

The S&P 500 index SPX, +0.62% finished up 13.10 points, or 0.6%, at 2,139.60, with all 11 main sectors trading higher.

The Dow Jones Industrial Average DJIA, +0.42% rose 75.54 points, or 0.4%, to close at 18,161.94.

Meanwhile, the Nasdaq Composite Index COMP, +0.85% added 44.01 points, or 0.9%, to close at 5,243.84.

Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) opened at $24.18 on Monday trading between $23.53 and $24.47, and last traded at $23.65, which is a drop of $0.68 per share or -2.79% compared to the previous closing price.

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) now has a market cap of 2.70B.

Acadia Pharmaceuticals Inc.Trading Volume

The stock’s average daily volume is 2,170,360 shares out of a total float 89,055,000 and some 318,678 shares traded hands yesterday, lower than the norm. Momentum traders often use upticks in trading volume to identify substantial volume aggregation or circulation by institutional investors, so look for trading volume to pick up in the coming days.

However, just a day of heavy buy side trading is not enough to affirm a trend. So market traders will continue to watch for institutional sponsorship as a cue that financial institutions are moving forward.

Institutional sponsorship just refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors retain substantial teams of analysts that research thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.

Acadia Pharmaceuticals Inc. Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By spotting trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.

With that in mind, Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) now has a 50-day MA of $31.04 and 200-day MA of $33.12. It has traded in a 52-week range between $16.64 – 43.30 and today’s last price is 45.38%% lower than the 52 week high of $43.30.

Indeed, earnings growth is among the most crucial things to look at in regards to stock investing and, accordingly, investors seek companies that have increased their earnings by at least 25% for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *